Gowthami Morey Arepally, MD

Professor of Medicine
Associate Professor of Pathology
Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and complement-mediated diseases.  Dr. Arepally’s long-standing research program investigates the immune pathogenesis of heparin induced thrombocytopenia (HIT).  Current laboratory efforts focus on the role of complement activation in antibody production and thrombosis in HIT, studies of complement inhibitors for immune-complex mediated diseases and diagnostic biomarkers of platelet activation.  

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Reed, Christopher R., Desiree Bonadonna, James C. Otto, Charles Griffin McDaniel, Charlene Vongai Chabata, Maragatha Kuchibhatla, James Frederiksen, et al. “Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO.” Mol Ther Nucleic Acids 27 (March 8, 2022): 524–34. https://doi.org/10.1016/j.omtn.2021.12.011.

PMID
35036063
Full Text

Kram, Shawn J., Arzo Hamidi, Bridgette L. Kram, Gowthami Arepally, and Jerrold H. Levy. “The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices.” J Cardiothorac Vasc Anesth, February 26, 2022. https://doi.org/10.1053/j.jvca.2022.02.030.

PMID
35331630
Full Text

Khandelwal, Sanjay, Ayiesha Barnes, Lubica Rauova, Amrita Sarkar, Ann H. Rux, Serge V. Yarovoi, S Sergei Zaitsev, et al. “Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.” Blood 138, no. 21 (November 25, 2021): 2106–16. https://doi.org/10.1182/blood.2020009487.

PMID
34189574
Full Text

Schmitz, Robin, Zachary W. Fitch, Paul M. Schroder, Ashley Y. Choi, Miriam Manook, Janghoon Yoon, Mingqing Song, et al. “C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.” Nat Commun 12, no. 1 (September 15, 2021): 5456. https://doi.org/10.1038/s41467-021-25745-7.

PMID
34526511
Full Text

Dhoot, Roshni, Aman Kansal, Chauncy Handran, Tarek Haykal, James Ronald, Matthew Kappus, Gowthami M. Arepally, Mark Graham, and John J. Strouse. “Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.” Am J Hematol 96, no. 9 (September 1, 2021): 1180–82. https://doi.org/10.1002/ajh.26258.

PMID
34057234
Full Text

Barbour, T., M. Scully, G. Ariceta, S. Cataland, K. Garlo, N. Heyne, Y. Luque, et al. “Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.” Kidney International Reports 6, no. 6 (June 1, 2021): 1603–13. https://doi.org/10.1016/j.ekir.2021.03.884.

Full Text

Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.” Kidney Int 99, no. 5 (May 2021): 1244. https://doi.org/10.1016/j.kint.2021.03.008.

PMID
33892867
Full Text

Pages